AstraZeneca plc Company Profile (LON:AZN)

About AstraZeneca plc (LON:AZN)

AstraZeneca plc logoAstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: LON:AZN
  • CUSIP: N/A
  • Web:
  • Market Cap: £62.19 billion
  • Outstanding Shares: 1,266,000,000
Average Prices:
  • 50 Day Moving Avg: GBX 4,574.46
  • 200 Day Moving Avg: GBX 4,884.61
  • 52 Week Range: GBX 3,996 - GBX 5,520
  • Trailing P/E Ratio: 16.11
  • P/E Growth: 3.26
Sales & Book Value:
  • Annual Revenue: £21.74 billion
  • Price / Sales: 2.86
  • Book Value: GBX 10.78 per share
  • Price / Book: 4.56
  • Dividend Yield: 4.5%
  • EBIDTA: £5.91 billion
  • Net Margins: 8.83%
  • Return on Equity: 14.36%
  • Return on Assets: 2.84%
  • Average Volume: 2.30 million shs.

Frequently Asked Questions for AstraZeneca plc (LON:AZN)

What is AstraZeneca plc's stock symbol?

AstraZeneca plc trades on the London Stock Exchange (LON) under the ticker symbol "AZN."

How often does AstraZeneca plc pay dividends? What is the dividend yield for AstraZeneca plc?

AstraZeneca plc announced a dividend on Thursday, July 27th. Investors of record on Thursday, August 10th will be paid a dividend of GBX 68.90 per share on Monday, September 11th. This represents a yield of 1.35%. The ex-dividend date is Thursday, August 10th. The official announcement can be seen at this link. View AstraZeneca plc's Dividend History.

Where is AstraZeneca plc's stock going? Where will AstraZeneca plc's stock price be in 2017?

21 equities research analysts have issued 12-month price targets for AstraZeneca plc's shares. Their forecasts range from GBX 3,800 to GBX 6,500. On average, they expect AstraZeneca plc's share price to reach GBX 5,114.19 in the next year. View Analyst Ratings for AstraZeneca plc.

Who are some of AstraZeneca plc's key competitors?

Who are AstraZeneca plc's key executives?

AstraZeneca plc's management team includes the folowing people:

  • Pascal Soriot, Executive Director and Chief Executive Officer
  • Marc Dunoyer, Executive Director, Chief Financial Officer
  • Fiona Cicconi, Executive Vice-President, Human Resources
  • Sean Bohen M.D., Ph.D., Chief Medical Officer, Executive Vice President - Global Medicines Development
  • Pam P. Cheng, Executive Vice President - Operations and Information Technology
  • Ruud Dobber, Executive Vice President, North America
  • Bahija Jallal Ph.D., Executive Vice President, MedImmune
  • Mark Mallon, Executive Vice President, Global Product and Portfolio Strategy, Global Medical Affairs & Corporate Affairs Executive Vice-President, International West
  • Menelas Pangalos, Executive Vice President - IMED Biotech Unit and Global Business Development
  • Leon Wang, Executive Vice President - Asia Pacific

How do I buy AstraZeneca plc stock?

Shares of AstraZeneca plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is AstraZeneca plc's stock price today?

One share of AstraZeneca plc stock can currently be purchased for approximately GBX 4,912.

MarketBeat Community Rating for AstraZeneca plc (LON AZN)
Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  887 (Thanks for Voting!)
Underperform Votes:  1,227 (Thanks for Voting!)
Total Votes:  2,114
MarketBeat's community ratings are surveys of what our community members think about AstraZeneca plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for AstraZeneca plc (LON:AZN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Sell Ratings, 8 Hold Ratings, 10 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: GBX 5,114.19

Analysts' Ratings History for AstraZeneca plc (LON:AZN)
DateFirmActionRatingPrice TargetDetails
9/25/2017Barclays PLCReiterated RatingOverweightGBX 6,300View Rating Details
9/25/2017Shore CapitalReiterated RatingHoldView Rating Details
9/25/2017Sanford C. BernsteinSet Price TargetBuyGBX 5,780View Rating Details
9/21/2017Societe GeneraleReiterated RatingBuyView Rating Details
9/19/2017Berenberg BankSet Price TargetBuyGBX 5,800View Rating Details
9/18/2017Jefferies Group LLCSet Price TargetNeutralGBX 4,900View Rating Details
9/14/2017Liberum CapitalDowngradeBuy -> HoldGBX 4,800 -> GBX 5,000View Rating Details
9/14/2017J P Morgan Chase & CoReiterated RatingNeutralGBX 4,500View Rating Details
9/13/2017Citigroup Inc.Set Price TargetBuyGBX 6,000View Rating Details
9/11/2017BNP ParibasSet Price TargetNeutralGBX 5,300View Rating Details
9/11/2017Kepler Capital MarketsReiterated RatingBuyGBX 5,200View Rating Details
9/11/2017Bryan, Garnier & CoUpgradeBuyGBX 4,700 -> GBX 5,380View Rating Details
9/11/2017Goldman Sachs Group, Inc. (The)Reiterated RatingSellGBX 3,800View Rating Details
9/11/2017Deutsche Bank AGBoost Price TargetBuyGBX 5,300 -> GBX 5,600View Rating Details
9/11/2017HSBC Holdings plcReiterated RatingReduceGBX 4,100View Rating Details
9/11/2017Credit Suisse GroupReiterated RatingNeutralGBX 4,700View Rating Details
9/6/2017NatixisUpgradeNeutral -> BuyGBX 5,000 -> GBX 5,738View Rating Details
8/9/2017InvestecUpgradeHold -> BuyGBX 5,000 -> GBX 4,900View Rating Details
7/28/2017Morgan StanleyDowngradeEqual WeightGBX 5,600 -> GBX 4,700View Rating Details
7/28/2017Beaufort SecuritiesDowngradeSellGBX 3,900View Rating Details
7/27/2017S&P GlobalSet Price TargetNeutralGBX 4,500View Rating Details
6/24/2016Independent Research GmbHSet Price TargetSellGBX 3,650View Rating Details
5/10/2016Oddo SecuritiesReiterated RatingBuyGBX 5,400View Rating Details
5/5/2016Charles StanleyUpgradeStrong-BuyView Rating Details
3/23/2016NomuraLower Price TargetHoldGBX 4,880 -> GBX 4,350View Rating Details
2/12/2016Baader BankReiterated RatingHoldGBX 4,400View Rating Details
2/9/2016AlphaValueUpgradeBuyGBX 4,640View Rating Details
2/4/2016S&P Equity ResearchSet Price TargetNeutralGBX 4,500View Rating Details
2/2/2016HandelsbankenReiterated RatingAccumulateGBX 5,220.30View Rating Details
1/28/2016Pareto SecuritiesReiterated RatingSellGBX 3,855.35View Rating Details
1/27/2016SwedbankReiterated RatingBuyGBX 5,115.47View Rating Details
1/13/2016Nordea Equity ResearchReiterated RatingHoldGBX 4,698.35View Rating Details
(Data available from 9/25/2015 forward)


Earnings History for AstraZeneca plc (LON:AZN)
No earnings announcements for this company have been tracked by


Earnings Estimates for AstraZeneca plc (LON:AZN)
Current Year EPS Consensus Estimate: $3.76 EPS


Dividend History by Quarter for AstraZeneca plc (LON AZN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/27/2017GBX 68.901.35%8/10/20178/10/20179/11/2017
2/2/2017GBX 150.203.52%2/16/20172/16/20173/20/2017
7/28/2016GBX 68.701.37%8/11/20168/11/20169/12/2016
2/4/2016GBX 1313.16%2/18/20162/18/20163/21/2016
7/30/2015GBX 57.501.33%8/13/20158/13/20159/14/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for AstraZeneca plc (LON:AZN)
Insider Trades by Quarter for AstraZeneca plc (LON:AZN)
Insider Trades by Quarter for AstraZeneca plc (LON:AZN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/27/2017Nazneen RahmanInsiderBuy39GBX 4,370£1,704.30
10/27/2015Courtois,Jean-PhilippeInsiderBuy900GBX 4,423£39,807
8/28/2015Soriot,PascalInsiderBuy76,300GBX 3,960£3,021,480
5/7/2015Marc DunoyerInsiderBuy10,000GBX 4,397£439,700
4/30/2015Ann CairnsInsiderBuy1,100GBX 4,455£49,005
4/29/2015Shriti VaderaInsiderBuy3,500GBX 4,563£159,705
4/28/2015Graham ChipchaseInsiderBuy1,100GBX 4,606£50,666
4/27/2015Bruce BurlingtonInsiderBuy600GBX 4,662£27,972
(Data available from 1/1/2013 forward)


Headline Trends for AstraZeneca plc (LON:AZN)
Latest Headlines for AstraZeneca plc (LON:AZN)
DateHeadline logoBerenberg Bank Analysts Give AstraZeneca plc (AZN) a GBX 5,800 Price Target - September 24 at 2:08 PM logoSociete Generale Reiterates "Buy" Rating for AstraZeneca plc (AZN) - September 23 at 5:22 PM logoWhy I’d ditch this defensive dividend stock to buy AstraZeneca plc - September 18 at 4:43 PM logoAstraZeneca plc (AZN) PT Set at GBX 4,900 by Jefferies Group LLC - September 18 at 6:30 AM logoAstraZeneca plc (AZN) Given a GBX 6,000 Price Target by Citigroup Inc. Analysts - September 17 at 7:38 PM logoAstraZeneca plc (AZN) Stock Rating Reaffirmed by J P Morgan Chase & Co - September 17 at 1:32 PM logoLiberum Capital Downgrades AstraZeneca plc (AZN) to Hold - September 17 at 11:38 AM logoBarclays PLC Analysts Give AstraZeneca plc (AZN) a GBX 6,300 Price Target - September 13 at 6:04 PM logoBreakfast Technical Briefing on Drug Makers Stocks -- AbbVie, AstraZeneca ... - September 13 at 5:28 PM logoBreakfast Technical Briefing on Drug Makers Stocks -- AbbVie, AstraZeneca, Bristol Myers Squibb, and Johnson & Johnson - September 13 at 5:28 PM logoAstraZeneca's Asthma Candidate Shows Promising Results - September 12 at 4:32 PM logoAstraZeneca plc (AZN) Given a GBX 4,550 Price Target by UBS AG Analysts - September 12 at 12:40 AM logoAstraZeneca plc (AZN) Given a GBX 5,300 Price Target at BNP Paribas - September 12 at 12:08 AM logoAstraZeneca Spikes After Lung Cancer Treat Study Shows 'Encouraging' Results - September 11 at 4:53 PM logoAstraZeneca Wins in Cancer by Going Its Own Way - September 11 at 4:53 PM logoAstraZeneca (AZN) Presents At European Society For Medical Oncology Annual Congress - Slideshow - September 11 at 4:52 PM logoAstraZeneca plc's (AZN) Buy Rating Reiterated at Berenberg Bank - September 11 at 9:30 AM logoAstraZeneca plc (AZN) Given "Neutral" Rating at J P Morgan Chase & Co - September 9 at 8:18 PM logoAstraZeneca CEO, worried by Brexit, not signing UK government letter - September 9 at 4:03 PM logoAstraZeneca CEO, worried by Brexit, not signing UK government letter - September 9 at 4:03 PM logoAstraZeneca plc (AZN) Receives Average Recommendation of "Hold" from Brokerages - September 9 at 6:26 AM logoAstraZeneca rebuilds cancer drug hopes with new lung data - September 8 at 9:43 PM logo[$$] AstraZeneca looks for boost from positive trials - September 8 at 9:43 PM logoAstraZeneca shares tick higher on lung cancer drug study results - September 8 at 9:43 PM logoMerck's immunotherapy, chemo mix shows extended lung cancer gains - September 7 at 9:26 PM logoAstraZeneca Announces Results From PATHWAY Phase IIb Trial Of Tezepelumab - September 7 at 4:23 PM logoAstraZeneca's COPD Candidate Duaklir Reports Positive Data - September 7 at 4:23 PM logoCitigroup Inc. Reiterates GBX 6,000 Price Target for AstraZeneca plc (AZN) - September 7 at 7:18 AM logoAstraZeneca plc (AZN) Upgraded by Natixis to "Buy" - September 6 at 7:20 AM logoAstraZeneca plc (AZN) Receives "Neutral" Rating from J P Morgan Chase & Co - September 5 at 12:32 AM logoNikkei climbs to 2-week highs as U.S. data bolsters dollar-yen - August 31 at 3:38 AM logoJefferies Group LLC Lowers AstraZeneca plc (AZN) Price Target to GBX 4,350 - August 27 at 8:32 PM logo[$$] AstraZeneca reverses stance with plan for UK investment - August 27 at 3:58 PM logoAstraZeneca plc's (AZN) Buy Rating Reaffirmed at Liberum Capital - August 21 at 7:14 PM logoAstraZeneca plc (AZN) Earns "Hold" Rating from Shore Capital - August 20 at 12:50 AM logoGoldman Sachs Group, Inc. (The) Analysts Give AstraZeneca plc (AZN) a GBX 3,900 Price Target - August 20 at 12:50 AM logoFDA Nod For PFE, New Use For AZN's Ovarian Cancer Drug, ELGX's LEOPARD Hits Goal - Nasdaq - August 18 at 3:44 AM logoBRIEF-Astrazeneca says non-exec director Burlington to retire - August 16 at 3:19 AM logoAstraZeneca plc (AZN) Given Consensus Recommendation of "Hold" by Analysts - August 15 at 6:50 AM logoEdited Transcript of AZN.L earnings conference call or presentation 27-Jul-17 12:30pm GMT - August 13 at 3:55 PM logoBrexit Is Quietly Killing Science - August 8 at 1:36 AM logoEx-Dividend Reminder: Wal-Mart Stores, Nexstar Media Group and AstraZeneca - Nasdaq - August 7 at 3:24 PM logo3 High-Yield Stocks for Aggressive Investors - August 7 at 2:26 PM logoAstraZeneca Takes a Long Shot on Lung Cancer Drug Study - August 7 at 1:54 AM logoAstraZeneca plc: Buy the Dip? - Motley Fool - August 4 at 4:40 PM logoWhy AstraZeneca plc Stock Broke Down in July - Motley Fool - August 4 at 4:40 PM logoWhy AstraZeneca plc Stock Broke Down in July - August 4 at 10:51 AM logoAstraZeneca plc: Buy the Dip? - August 3 at 8:22 PM logoAstraZeneca Stages Major Lung Cancer Comeback - Seeking Alpha - August 3 at 3:05 AM logoAstraZeneca Gets The Bad News - Seeking Alpha - August 2 at 10:03 PM


Social activity is not available for this stock.


AstraZeneca plc (AZN) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by Staff